Startup profile for Capra Biosciences: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Capra Biosciences funding, valuation and investors

Modular biomanufacturing for chemicals and pharmaceutical ingredients.

Verified company research · funding, investors and latest developments

Keep track of Capra Biosciences

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Pre-Seed

$1.8M · June 6, 2022

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$1.8M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

Stage not recorded · Sterling, Virginia, United States

Investors in latest funding

Other: Prithvi Ventures , E14 Fund , GS Futures , Wes Osbourn , Savantus Ventures , Asymmetry Ventures , Decarbonization Consortium , SOSV

Sources: latest funding · pwcded.org Last verified: 2026-11-15

Overview

Capra Biosciences develops continuous bioreactor technology and modular facilities for producing high-value chemicals. Its early work included retinol, while current company disclosures describe pharmaceutical ingredients, personal care, defense and industrial markets. A June 2022 announcement named Prithvi Ventures among participants in its $1.8 million pre-seed round.

Later government project funding is a separate financing category and should not be added to venture equity as though it were the same instrument.

Why Capra Biosciences is interesting

Capra's model combines biological production with reactor engineering and facility operations. Its commercial milestones include repeatable product quality, scale-up, customer qualification and the ability to supply molecules reliably within domestic supply chains.

Product & use cases

The platform integrates production organisms, modular reactors and continuous processing. Company product disclosures identify retinol among products in supply. An August 2026 update described continued ASPR support for domestic pharmaceutical-ingredient manufacturing; that project support does not establish another Prithvi equity investment.

  • Biomanufacturing of retinol for personal-care formulators.
  • Domestic production development for pharmaceutical ingredients.
  • Flexible manufacturing of high-value small molecules.

Key facts

  • Prithvi is named in the June 6, 2022 $1.8M pre-seed announcement.
  • Platform combines biological production with modular continuous reactors.
  • Government project funding is tracked separately from venture equity.

Funding history (newest first)

Pre-Seed

2022-06-06 $1.8M
  • Prithvi Ventures (participant)
  • E14 Fund (participant)
  • GS Futures (participant)
  • Wes Osbourn (participant)
  • Savantus Ventures (participant)
  • Asymmetry Ventures (participant)
  • Decarbonization Consortium (participant)
  • SOSV (participant)

Source: Read source · pwcded.org

Investors in our directory

Funds linked from Capra Biosciences's profile — open a fund page for stage focus and related deal articles.

Industries

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Capra Biosciences

Practical answers founders, operators, and investors typically search for.

It develops modular biomanufacturing facilities and continuous bioreactor technology for chemicals and pharmaceutical ingredients.
Yes. The June 6, 2022 pre-seed announcement explicitly names Prithvi among investors. The $1.8M amount is the entire round, not Prithvi's individual check.
Capra lists product status at https://www.caprabiosciences.com/products and its current platform at https://www.caprabiosciences.com/platform.html.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.